SGLT2 Inhibitors
SGLT2 Inhibitors
SGLT2 inhibitors are oral medicines that reduce blood sugar by helping the kidneys excrete glucose in urine. These agents support type 2 diabetes care and can aid certain heart and kidney outcomes, with US shipping from Canada for eligible orders. Their mechanism of action in diabetes involves blocking the sodium‑glucose cotransporter‑2 in the proximal tubule, which lowers glucose reabsorption and promotes mild diuresis. You can compare brands, tablet strengths, and combination products side by side. Stock and pack sizes can vary over time, and listings may change without notice.
What’s in This Category
This section includes individual tablets and fixed‑dose combinations taken once daily. You will see a sglt2 inhibitors list featuring empagliflozin, dapagliflozin, and canagliflozin, alongside dual products that pair them with metformin. Explore broader therapy groupings under Diabetes Medications and specifically within Non‑Insulin Medications. For combination therapy, look at empagliflozin/metformin combinations and the dapagliflozin/metformin combination, which can simplify dosing and pill burden. These options come as scored tablets in common strengths, typically taken in the morning.
Adults with type 2 diabetes are the usual audience, including those with chronic kidney disease or heart failure who need cardio‑renal benefit. These products are tablets, not an sglt2 inhibitors injection, and they are not indicated for type 1 diabetes or diabetic ketoacidosis. Many users also compare expected sglt2 inhibitors cost, potential copay differences, and whether a generic exists. Kidney function matters for initiation and continuation, reflecting the class’s mechanism of action in kidney tubules. Always check your current medicines and clinical goals when scanning a drugs list within this class.
How to Choose
Start with your primary indication and kidney function. Some products have specific eGFR thresholds for initiation, and dose adjustments may apply with reduced renal function. Discuss SGLT2 inhibitors if you need glucose control with added heart and kidney benefits. Compare tablet strengths, morning versus flexible dosing, and whether a combination tablet could replace separate metformin. When labels differ, a quick personal dose comparison chart can help you organize choices to review with your clinician.
Screen for volume depletion, diuretic intensity, and history of genital mycotic infections. Review rare risks like ketoacidosis during acute illness and amputation risk signals associated with canagliflozin. Consider pregnancy planning, perioperative holds, and any contraindications related to very low eGFR. Storage is simple at room temperature; keep tablets dry and in original packaging. If you are comparing alternative oral classes, scan DPP‑4 Inhibitors for options that work through a different pathway.
Popular Options
Jardiance 10 mg and 25 mg is widely used for A1C reduction and heart‑failure risk reduction in appropriate adults. Many start with the lower tablet and titrate if needed under supervision. Dapagliflozin is available as Farxiga (dapagliflozin), chosen for glucose control and kidney or heart indications per labeling. Review whether you also take metformin, since a single combination tablet can simplify your regimen.
If you prefer canagliflozin, consider canagliflozin tablets in typical strengths. Starting sglt2 inhibitors dosage commonly follows the lower labeled dose, with careful monitoring for hydration status and tolerability. For help aligning strengths with goals, see the Farxiga Dosing Guide for a practical illustration of dose steps and daily timing. Combination choices may suit those aiming to reduce pill counts while maintaining stable metformin intake.
Related Conditions & Uses
Evidence for sglt2 inhibitors heart failure includes benefits across preserved and reduced ejection fraction populations. Many patients without diabetes still use this class for heart‑failure outcomes when aligned with guideline‑directed care. For a broader clinical overview, read SGLT2 Inhibitors and Heart Failure to understand how cardiology teams integrate these agents. Mechanistic benefits extend to natriuresis and reduced intraglomerular pressure, which can support kidney health.
In chronic kidney disease, the mechanism of action in kidney tubules can reduce albuminuria and slow decline in function. Some people also notice modest weight changes, reflecting calorie loss in urine rather than a dedicated sglt2 inhibitors weight loss indication. Those comparing alternatives for glucose lowering might review Biguanides or Sulfonylureas if cost or contraindications influence selection. Emerging guidance covers heart failure without diabetes, HFpEF considerations, and practical dose choices within multidisciplinary care.
Authoritative Sources
For class safety updates, including sglt2 inhibitors side effects, see the FDA’s overview of adverse event signals and precautions here. You can also review American Heart Association and American College of Cardiology guidance on integrating this class in heart‑failure care in these guidelines. Health Canada has issued safety communications that outline monitoring and risk minimization measures for this class on this page.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.
Filter
Product price
Product categories
Conditions
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Frequently Asked Questions
Which medicines are included in this class?
This category includes tablets containing empagliflozin, dapagliflozin, or canagliflozin, plus fixed‑dose combinations with metformin. Strengths vary by product line, and some items are paired to reduce pill burden. You can browse single‑ingredient options or dual tablets and compare available strengths and pack sizes. Labels differ for diabetes, kidney disease, and heart‑failure indications, so check the specific product page before deciding which direction to discuss with your clinician.
Do I need a prescription to order?
A valid prescription is typically required for products in this class. The exact requirement depends on your location and the specific medicine selected. Before browsing, keep your current prescription details available, including the exact strength and dosing schedule. This helps you compare listings accurately and reduces order issues. If your prescription lists a combination tablet, filter results to match both active ingredients and their doses.
How do I choose between a single tablet and a combination?
Start with your care plan and current metformin dose. A combination tablet may reduce pill count if the metformin strength matches your needs. If not, a single SGLT2 agent plus separate metformin may offer more flexibility. Consider eGFR limits, infection risk, and your target A1C or cardio‑renal goals. Review tablet strengths, morning timing, and whether your insurance or budget favors one approach over another.
Are these tablets suitable with reduced kidney function?
Kidney function guides initiation and dosing. Many products have eGFR thresholds for starting therapy and instructions for continuation as function changes. Your clinician may adjust timing or dose, or defer therapy when kidney function is very low. Review each product’s labeling for renal guidance. When comparing items on this page, note the listed strengths and any renal cautions shown on the product detail pages.
What side effects should I consider while browsing?
Common effects include increased urination and genital yeast infections. Less common risks include dehydration, low blood pressure, and ketoacidosis during acute illness or fasting. Some agents carry specific warnings about amputation risk. Monitor symptoms during dose changes and review interactions with diuretics or blood‑pressure medicines. Check each product page for safety highlights, and discuss any personal risk factors with your healthcare provider before starting a new medication.
Related Articles
Cardiovascular, Diabetes, Type
Mounjaro Heart Benefits Beyond Weight Loss: Evidence-Based Guide
Interest has grown around Mounjaro heart benefits as clinicians evaluate tirzepatide’s broader impact beyond glucose control and weight. Patients want clear, cautious guidance. This overview explains what current data suggests,…
Diabetes, Type 2
Ozempic Rebound: A Practical Guide to Prevent Weight Regain
Many people stop GLP-1 therapy and wonder what comes next. Appetite changes, routine shifts, and metabolism can collide. A clear plan helps you keep progress steady and predictable, not reactive.…
Cardiovascular, Diabetes
National Diabetes Heart Connection Day: A Practical Guide
National Diabetes Heart Connection Day spotlights how diabetes and cardiovascular risk intertwine. This guide explains the mechanisms, major risks, practical screening steps, and daily routines that support heart health. Use…
Diabetes
Common Diabetes Medications: How They Work and When to Use
Understanding common diabetes medications helps you discuss options with your clinician. This overview explains how major drug classes work, where they fit, and how they differ. You will also find…